Physician profile
Kishor E Joshi
NPI 1518970516
$7,329.53
in general payments reported to CMS, 2019-2025
27 companies · $561 in 2025
The $561 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,600 · 2020: $1,254 · 2021: $588 · 2022: $687 · 2023: $708 · 2024: $931 · 2025: $561.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,194 · Education: $6.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,193.91 |
| Education | $6.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,162.25 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Pfizer INC. | $952.76 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $891.45 | 2019-2024 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $762.95 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $734.39 | 2019-2025 | Farxiga, Lokelma, Breztri |
| Amgen INC. | $432.27 | 2019-2025 | Repatha, Repatha |
| Lilly USA, LLC | $420.56 | 2019-2025 | Jardiance, Mounjaro, Trulicity |
| Glaxosmithkline, LLC. | $266.00 | 2019-2023 | Trelegy Ellipta |
| Abbott Laboratories | $247.63 | 2021-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Abbvie INC. | $220.43 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $204.39 | 2019-2025 | Jardiance |
| Allergan, INC. | $198.60 | 2019 | |
| Merck Sharp & Dohme LLC | $132.12 | 2019-2025 | Verquvo |
| Novartis Pharmaceuticals Corporation | $127.43 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $123.73 | 2019-2023 | Eliquis |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $96.53 | 2019-2020 | |
| Vifor Pharma, INC. | $68.13 | 2019-2022 | |
| Astellas Pharma US INC | $55.52 | 2020-2021 | |
| Esperion Therapeutics, INC. | $52.80 | 2024-2025 | Nexletol |
| Intuitive Surgical, INC. | $33.27 | 2019 | |
| Redhill Biopharma INC. | $32.90 | 2021-2022 | |
| Amarin Pharma, INC. | $28.83 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.55 | 2021 | |
| Seqirus USA INC | $18.35 | 2019 | |
| Sunovion Pharmaceuticals INC. | $17.06 | 2019 | |
| Tactile Systems Technology INC | $16.22 | 2025 | Flexitouch Plus, Nimbl |
| Sanofi-Aventis U.S. LLC | $12.41 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kishor Joshi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.